NGD-4715
Identifiers
CAS Number
Chemical and physical data
FormulaC25H30F3N3O3
Molar mass477.528 g·mol−1
3D model (JSmol)
  • [H][C@@]12CCC[C@@H](N1CCN(C2)C(=O)C1=CC=C(N=C1)C(F)(F)F)C1=CC=C(OCCO)C(C)=C1C

NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1.[1] In animal models it has anxiolytic, antidepressant, and anorectic effects,[2] and it has successfully passed Phase I clinical trials in humans.[3]

Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets.[4] All four laboratories were closed and sold, and no employees were retained.[5]

The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.[6]

References

  1. ^ Tarrant J, Hodgetts KJ, Chenard BL, Krause JE, Doller D (2017). "The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity". Comprehensive Medicinal Chemistry III. pp. 488–515. doi:10.1016/B978-0-12-409547-2.13785-0. ISBN 9780128032015.
  2. ^ Chaki S, Kanuma K (2007). "Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders". Drugs of the Future. 32 (9): 809. doi:10.1358/dof.2007.032.09.1131450.
  3. ^ "Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity". Business Wire. 2 May 2007.
  4. ^ "Neurogen acquired by Ligand Pharmaceuticals". Business Wire. 24 August 2009.
  5. ^ "Neurogen to sell Real Estate for $3.5m". Chicago Tribune. 10 November 2009.
  6. ^ "NGD-4715". PubChem. U.S. National Library of Medicine.


Categories